StocksFundsScreenerSectorsWatchlists
KPTI

KPTI - Karyopharm Therapeutics Inc Stock Price, Fair Value and News

1.52USD+0.04 (+2.70%)Delayed as of 28 Mar 2024, 11:03 am ET

Market Summary

KPTI
USD1.52+0.04
Delayedas of 28 Mar 2024, 11:03 am
2.70%

KPTI Stock Price

View Fullscreen

KPTI RSI Chart

KPTI Valuation

Market Cap

170.3M

Price/Earnings (Trailing)

-1.19

Price/Sales (Trailing)

1.17

EV/EBITDA

-1

Price/Free Cashflow

-1.84

KPTI Price/Sales (Trailing)

KPTI Profitability

EBT Margin

-97.77%

Return on Equity

105.06%

Return on Assets

-59.52%

Free Cashflow Yield

-54.45%

KPTI Fundamentals

KPTI Revenue

Revenue (TTM)

146.0M

Rev. Growth (Yr)

0.5%

Rev. Growth (Qtr)

-6.28%

KPTI Earnings

Earnings (TTM)

-143.1M

Earnings Growth (Yr)

-8.65%

Earnings Growth (Qtr)

-21.25%

Breaking Down KPTI Revenue

52 Week Range

1.114.87
(Low)(High)

Last 7 days

-7.9%

Last 30 days

9.5%

Last 90 days

69.5%

Trailing 12 Months

-59.1%

How does KPTI drawdown profile look like?

KPTI Financial Health

Current Ratio

3.37

KPTI Investor Care

Shares Dilution (1Y)

1.52%

Diluted EPS (TTM)

-1.25

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2023148.1M146.0M145.9M146.0M
2022234.2M251.3M249.8M157.1M
2021113.2M102.3M118.7M209.8M
202058.9M82.9M91.1M108.1M
201933.0M35.6M38.3M40.9M
201816.5M31.4M31.7M30.3M
2017222.0K567.8K1.3M1.6M
20160309.0K207.0K179.0K
20150208.0K262.0K266.0K
2014325.0K213.0K234.0K229.0K
2013833.0K433.0K399.0K387.0K
2012272.5K393.0K513.5K634.0K
2011000152.0K

Tracking the Latest Insider Buys and Sells of Karyopharm Therapeutics Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Mar 05, 2024
paulson richard a.
sold
-4,644
1.3
-3,573
president and ceo
Mar 01, 2024
mason michael
sold
-7,394
1.2
-6,162
evp, cfo & treasurer
Mar 01, 2024
paulson richard a.
sold
-23,248
1.2
-19,374
president and ceo
Mar 01, 2024
rangwala reshma
sold
-7,162
1.2
-5,969
evp & chief medical officer
Mar 01, 2024
mano michael
sold
-4,291
1.2
-3,576
svp, general counsel&secretary
Mar 01, 2024
cheng sohanya roshan
sold
-6,130
1.2
-5,109
evp & chief commercial officer
Mar 01, 2024
poulton stuart
sold
-7,386
1.2
-6,155
evp, chief development officer
Feb 29, 2024
mano michael
sold
-19,858
1.17
-16,973
svp, general counsel&secretary
Feb 29, 2024
mason michael
sold
-32,393
1.17
-27,687
evp, cfo & treasurer
Feb 29, 2024
cheng sohanya roshan
sold
-25,552
1.17
-21,840
evp & chief commercial officer

1–10 of 50

Which funds bought or sold KPTI recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Mar 22, 2024
PNC FINANCIAL SERVICES GROUP, INC.
unchanged
-
-1,425
2,595
-%
Mar 11, 2024
VANGUARD GROUP INC
reduced
-1.24
-4,284,420
7,534,290
-%
Mar 01, 2024
GOLDMAN SACHS GROUP INC
added
35.41
-323,057
2,243,110
-%
Feb 28, 2024
AMERICAN INTERNATIONAL GROUP, INC.
reduced
-0.4
-27,046
48,695
-%
Feb 26, 2024
Virtu Financial LLC
new
-
9,000
9,000
-%
Feb 16, 2024
HARBOUR INVESTMENTS, INC.
unchanged
-
-617
1,125
-%
Feb 16, 2024
GSA CAPITAL PARTNERS LLP
added
311
1,260,000
2,022,000
0.17%
Feb 16, 2024
PRICE T ROWE ASSOCIATES INC /MD/
unchanged
-
-41,000
76,000
-%
Feb 15, 2024
WEXFORD CAPITAL LP
new
-
23,597
23,597
-%
Feb 15, 2024
BARCLAYS PLC
reduced
-15.82
-706,000
838,000
-%

1–10 of 41

Are Funds Buying or Selling KPTI?

Are funds buying KPTI calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own KPTI
No. of Funds

Unveiling Karyopharm Therapeutics Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
avidity partners management lp
9.5%
11,188,743
SC 13G/A
Feb 14, 2024
palo alto investors lp
4.45%
5,102,193
SC 13G/A
Feb 13, 2024
vanguard group inc
7.60%
8,710,158
SC 13G
Feb 12, 2024
rubric capital management lp
0%
0
SC 13G/A
Jan 25, 2024
blackrock inc.
8.8%
10,071,677
SC 13G/A
Jan 22, 2024
state street corp
1.79%
2,053,773
SC 13G/A
Jul 10, 2023
state street corp
1.94%
2,212,367
SC 13G/A
Feb 14, 2023
avidity partners management lp
9.9%
11,381,073
SC 13G/A
Feb 14, 2023
palo alto investors lp
5.00%
5,655,676
SC 13G/A
Feb 14, 2023
chione ltd
3.9%
4,400,000
SC 13G/A

Recent SEC filings of Karyopharm Therapeutics Inc

View All Filings
Date Filed Form Type Document
Mar 06, 2024
4
Insider Trading
Mar 04, 2024
4
Insider Trading
Mar 04, 2024
4
Insider Trading
Mar 04, 2024
4
Insider Trading
Mar 04, 2024
4
Insider Trading
Mar 04, 2024
4
Insider Trading
Mar 04, 2024
4
Insider Trading
Feb 29, 2024
10-K
Annual Report
Feb 29, 2024
8-K
Current Report
Feb 29, 2024
4
Insider Trading

Peers (Alternatives to Karyopharm Therapeutics Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
42.3B
6.8B
19.31% -24.90%
-8.96
6.17
-64.45% -156.37%
22.4B
152.6K
-0.77% 465779.94%
-2.4K
146.8K
- -9.98%
19.4B
1.8B
-0.33% -18.28%
-44.17
10.64
76.23% 61.08%
16.7B
2.4B
-4.10% -7.32%
99.73
6.91
15.42% 18.43%
12.8B
3.7B
-1.69% -18.94%
21.46
3.47
8.87% 75.42%
MID-CAP
7.1B
396.6M
-19.47% -8.81%
-13.34
17.78
425.83% 18.94%
5.4B
-
-20.51% 118.30%
-8.31
60.35
54.84% -34.79%
3.8B
270.6M
-13.09% 29.37%
-15.68
13.86
440.80% -27.84%
3.6B
240.7M
-7.70% 7.49%
-11.98
14.77
-1.03% -92.09%
3.0B
726.4M
-28.51% -9.28%
-48.93
4.13
40.45% 71.62%
SMALL-CAP
1.9B
398.2M
12.36% 9.77%
26.85
4.82
85.90% -14.05%
678.8M
983.7M
12.98% -18.87%
-1.25
0.69
-50.36% 17.16%
373.2M
881.7K
51.26% 463.55%
-8.37
466.16
-77.61% -5.33%
304.5M
4.9M
46.53% -11.16%
-2.25
62.57
-54.97% 51.72%
11.8M
2.1M
-13.49% -43.81%
-0.43
2.14
-13.45% 66.37%

Karyopharm Therapeutics Inc News

Latest updates
MarketBeat39 hours ago
CNN31 Jan 202402:15 am

Karyopharm Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Revenue-6.3%33,747,00036,009,00037,579,00038,698,00033,580,00036,145,00039,679,00047,670,000126,269,00037,689,00022,601,00023,260,00035,100,00021,333,00033,514,00018,138,00018,096,00013,149,0009,493,0004,849,500206,000
Operating Expenses6.4%71,555,00067,269,00067,152,00069,597,00067,449,00066,984,00082,587,00082,256,00079,307,00081,501,00071,649,00075,633,00072,166,00068,442,00073,833,00065,494,00061,362,00052,550,00051,179,00065,077,00057,661,000
  S&GA Expenses-0.4%30,688,00030,805,00034,481,00035,907,00034,649,00034,645,00037,339,00038,768,00034,562,00035,104,00036,530,00037,650,00033,929,00030,967,00030,843,00030,678,00028,389,00025,267,00024,662,00027,103,00018,771,000
  R&D Expenses10.8%39,381,00035,553,00031,477,00032,339,00030,932,00031,359,00044,309,00042,062,00044,003,00045,808,00033,981,00037,050,00037,185,00037,037,00042,594,00033,997,00031,579,00026,270,00026,517,00037,974,00038,890,000
EBITDA Margin-2.5%-0.81-0.79-0.80-0.90-0.89-0.24-0.29-0.34-0.46-1.51-1.79-1.53---------
Interest Expenses2.2%6,208,0006,073,0005,784,0005,758,0005,885,0006,114,0006,313,0006,684,0007,940,0008,010,0005,001,0005,095,0007,072,0006,801,0006,758,0006,509,0006,467,0003,093,0003,089,0002,998,000-
Income Taxes983.3%130,00012,000127,00054,00073,00045,000121,000130,000-89,000106,000134,000149,00053,00044,000137,00066,0002,00020,0008,00010,00017,000
Earnings Before Taxes-20.9%-41,707,000-34,494,000-32,503,000-34,072,000-38,433,000-36,279,000-48,941,000-41,269,00038,599,000-51,706,000-53,448,000-57,265,000-43,359,000-53,451,000-46,289,000-52,865,000-48,645,000-41,347,000-43,407,000-66,151,000-58,193,000
EBT Margin-2.2%-0.98-0.96-0.97-1.06-1.05-0.35-0.41-0.46-0.59-1.73-2.03-1.77---------
Net Income-21.2%-41,837,000-34,506,000-32,630,000-34,126,000-38,506,000-36,324,000-49,062,000-41,399,00038,720,000-51,812,000-53,582,000-57,414,000-43,421,000-53,495,000-46,426,000-52,931,000-48,647,000-41,367,000-43,415,000-66,161,000-58,210,000
Net Income Margin-2.3%-0.98-0.96-0.97-1.07-1.05-0.35-0.41-0.46-0.59-1.74-2.03-1.77---------
Free Cashflow37.1%-18,585,000-29,530,000-25,698,000-18,910,000-26,843,000-28,409,000-35,144,000-59,276,00025,268,000-23,960,000-55,748,000-52,888,000---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Assets-10.9%240270298326358231256294305254287275313338380416295298238287341
  Current Assets-11.1%234263291319350223242277276242274256277285318371279281223271335
    Cash Equivalents19.6%52.0044.0081.0084.0013571.0082.0015319013714188.0089.0082.0010320213116876.0084.00119
  Inventory-2.0%3.003.004.004.004.004.003.004.004.004.004.003.003.002.002.001.000.000.00---
  Net PPE-11.7%1.001.001.001.001.001.001.002.002.002.002.002.002.002.003.003.003.003.003.004.004.00
Liabilities1.7%377370369371375372373377385380370315263254250250245238156166158
  Current Liabilities11.9%69.0062.0059.0062.0066.0062.0063.0066.0074.0069.0058.0062.0060.0053.0051.0050.0046.0039.0032.0044.0047.00
Shareholder's Equity-Infinity%-136----16.66----79.67---51.0084.0013016650.0060.0082.00121183
  Retained Earnings-2.9%-1,487-1,445-1,410-1,378-1,343-1,305-1,269-1,220-1,178-1,217-1,165-1,111-15.00-1,026-972-926-873-824-783-739-673
  Additional Paid-In Capital0.4%1,3511,3461,3401,3331,3281,1661,1531,1371,0991,0911,0821,0721,1201,1091,1021,093923885866861857
Shares Outstanding0.3%11511511411411380.0079.0078.0075.0075.0075.0075.00---------
Float---201---351---739---1,320---344--
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Cashflow From Operations37.1%-18,585-29,530-25,698-18,910-26,843-28,370-35,144-59,19725,475-23,955-55,748-52,888-30,634-44,312-40,277-45,011-39,489-36,506-48,204-66,623-48,172
  Share Based Compensation2.0%5,1825,0786,0605,3896,1736,79715,0937,3366,8697,4208,1357,3596,3146,5136,4285,1523,5493,7194,1163,9073,897
Cashflow From Investing449.3%26,843-7,68521,170-32,388-65,29811,673-36,596-14,03530,77021,42646,45843,18631,39721,431-60,034-46,479-33,51940,17539,80331,991-103,110
Cashflow From Financing-264-860-155,8435,7991,31330,78389616.0062,06010,6763,9681,2402,046164,82934,93688,822395152167,776

KPTI Income Statement

2023-12-31
Consolidated Statements of Operations - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Revenues:   
Revenue from contract with customer, license and other revenue$ 146,033$ 157,074$ 209,819
Operating expenses:   
Research and development138,750148,662160,842
Selling, general and administrative131,881145,401143,846
Total operating expenses275,573299,276308,090
Loss from operations(129,540)(142,202)(98,271)
Other income (expense):   
Interest income10,9432,359582
Interest expense(23,823)(24,996)(26,046)
Other expense, net(356)(83)(85)
Total other expense, net(13,236)(22,720)(25,549)
Loss before income taxes(142,776)(164,922)(123,820)
Income tax provision(323)(369)(268)
Net loss$ (143,099)$ (165,291)$ (124,088)
Net loss per share - basic$ (1.25)$ (2.02)$ (1.65)
Net loss per share - diluted$ (1.25)$ (2.02)$ (1.65)
Weighted-average number of common shares outstanding used to compute net loss per share - basic114,221,00081,871,00075,218,000
Weighted-average number of common shares outstanding used to compute net loss per share - diluted114,221,00081,871,00075,218,000
Product [Member]   
Revenues:   
Revenue from contract with customer, license and other revenue$ 112,011$ 120,445$ 98,436
Operating expenses:   
Cost of sales4,9425,2133,402
License and Other [Member]   
Revenues:   
Revenue from contract with customer, license and other revenue$ 34,022$ 36,629$ 111,383

KPTI Balance Sheet

2023-12-31
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 52,231$ 135,188
Investments139,212142,779
Accounts receivable,net26,96247,086
Inventory3,0434,224
Prepaid expenses and other current assets11,81319,821
Restricted cash6601,064
Total current assets233,921350,162
Property and equipment, net6061,139
Operating lease right-of-use assets4,2766,238
Restricted cash301633
Other assets1,3340
Total assets240,438358,172
Current liabilities:  
Accounts payable3,1232,773
Accrued expenses61,39458,415
Operating lease liabilities3,3082,872
Other current liabilities1,6541,848
Total current liabilities69,47965,908
Convertible senior notes170,919170,105
Deferred royalty obligation132,479132,718
Operating lease liabilities, net of current portion2,7896,097
Other liabilities9780
Total liabilities376,644374,828
Stockholders' deficit  
Preferred stock, $0.0001 par value; 5,000 shares authorized; none issued and outstanding00
Common stock, $0.0001 par value; 4000,000 shares authorized; 114,915 shares issued and outstanding at December 31, 2023; 200,000 shares authorized; 113,213 shares issued and outstanding at December 31, 20221212
Additional paid-in capital1,350,9811,327,909
Accumulated other comprehensive loss(161)(638)
Accumulated deficit(1,487,038)(1,343,939)
Total stockholders' deficit(136,206)(16,656)
Total liabilities and stockholders' deficit$ 240,438$ 358,172
KPTI
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The company is also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. The company was incorporated in 2008 and is headquartered in Newton, Massachusetts.
 CEO
 WEBSITEwww.karyopharm.com
 EMPLOYEES385

Karyopharm Therapeutics Inc Frequently Asked Questions


What is the ticker symbol for Karyopharm Therapeutics Inc? What does KPTI stand for in stocks?

KPTI is the stock ticker symbol of Karyopharm Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Karyopharm Therapeutics Inc (KPTI)?

As of Wed Mar 27 2024, market cap of Karyopharm Therapeutics Inc is 170.3 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of KPTI stock?

You can check KPTI's fair value in chart for subscribers.

What is the fair value of KPTI stock?

You can check KPTI's fair value in chart for subscribers. The fair value of Karyopharm Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Karyopharm Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for KPTI so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Karyopharm Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether KPTI is over valued or under valued. Whether Karyopharm Therapeutics Inc is cheap or expensive depends on the assumptions which impact Karyopharm Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for KPTI.

What is Karyopharm Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Mar 27 2024, KPTI's PE ratio (Price to Earnings) is -1.19 and Price to Sales (PS) ratio is 1.17. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. KPTI PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Karyopharm Therapeutics Inc's stock?

In the past 10 years, Karyopharm Therapeutics Inc has provided -0.289 (multiply by 100 for percentage) rate of return.